Benign Prostatic Hyperplasia (BPH)



Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: Group-1 (15mg, OPK-88004);   Drug: Group-2 (25 mg,OPK-88004);   Other: Placebo
Sponsor:   Transition Therapeutics Ireland Limited
Recruiting


AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: AquaBeam System
Sponsor:   PROCEPT BioRobotics
Completed


Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: AquaBeam System
Sponsor:   PROCEPT BioRobotics
Completed


Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: AquaBeam System
Sponsor:   PROCEPT BioRobotics
Completed


Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres


Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Prostate Artery Embolization
Sponsors:   Northwestern University;   BTG International Inc.
Recruiting


Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: Prostate Artery Embolization
Sponsor:   University of Minnesota - Clinical and Translational Science Institute
Recruiting


Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Device: Embosphere® (Prostatic Arteries Embolization);   Drug: Drug therapy
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Ministry of Health, France
Recruiting


Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams


Condition:   Prostatic Hyperplasia
Intervention:   Device: Embosphere Microspheres
Sponsor:   South Florida Medical Imaging, PA
Active, not recruiting


A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: talaporfin sodium;   Drug: Saline;   Device: Drug Activator 100 J/cm;   Device: Drug Activator 200 J/cm
Sponsors:   Light Sciences Oncology;   Mundipharma Research Limited
Completed


Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Intervention:   Drug: Embozene Microspheres
Sponsors:   Jena University Hospital;   Boston Scientific Corporation
Active, not recruiting


Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)


Condition:   Benign Prostatic Hyperplasia
Intervention:   Device: Microspheres
Sponsor:   University of North Carolina, Chapel Hill
Completed


Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia


Condition:   Prostatic Hyperplasia
Interventions:   Drug: Dutasteride 0.5mg capsules;   Drug: Dutasteride placebo capsules;   Drug: Tamsulosin 0.2mg tablets;   Drug: Disintegrating placebo tamsulosin tablet
Sponsor:   GlaxoSmithKline
Completed


Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Procedure: Prostatic artery embolization;   Procedure: monopolar transurethral prostatectomy
Sponsor:   Daniel Stephan Engeler
Active, not recruiting


Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)


Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Prostate Artery Embolization
Sponsor:   Northwestern University
Active, not recruiting


Prostate Embolization for Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Procedure: Prostatic Embolization;   Drug: Embosphere® Microspheres
Sponsor:   James B. Spies, MD
Completed


Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)


Condition:   Benign Prostatic Hyperplasia (BPH)
Intervention:   Device: Vortx Rx - Histotripsy BPH Device
Sponsor:   HistoSonics, Inc.
Active, not recruiting


Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Device: Embosphere Microspheres;   Procedure: TURP
Sponsor:   Merit Medical Systems, Inc.
Terminated


Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: Afalaza;   Drug: Placebo
Sponsor:   Materia Medica Holding
Completed


Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: Finasteride;   Drug: Tamsulosin;   Drug: Finasteride-matching placebo;   Drug: Tamsulosin-matching placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated


Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: Early combination therapy;   Drug: Delayed combination therapy
Sponsor:   GlaxoSmithKline
Completed


Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia


Condition:   Prostatic Hyperplasia
Interventions:   Drug: Adherent with 5-alpha-reductase inhibitor (5ARI) therapy;   Drug: Non-adherent to 5ARI therapy
Sponsor:   GlaxoSmithKline
Completed


Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: S-equol;   Drug: Placebo
Sponsor:   Ausio Pharmaceuticals, LLC
Completed


A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: placebo;   Drug: sildenafil
Sponsor:   Pfizer
Completed


PVP Compared to TURP for the Treatment of Benign Hyperplasia of the Prostate


Condition:   Benign Prostatic Hyperplasia
Interventions:   Device: GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)];   Procedure: Transurethral resection of the prostate
Sponsors:   St. Joseph's Healthcare Hamilton;   Ontario Ministry of Health and Long Term Care
Completed


A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)


Condition:   Benign Prostatic Hyperplasia
Interventions:   Drug: MK0906, finasteride / Duration of Treatment: 48 weeks;   Drug: Comparator: placebo / Duration of Treatment: 48 weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Refine Your Search Advanced Search